<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39355249</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1445653</StartPage><MedlinePgn>1445653</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1445653</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1445653</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">A clear immune correlate of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has not been defined. We explored antibody, B-cell, and T-cell responses to the third-dose vaccine and relationship to incident SARS-CoV-2 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Adults in a prospective cohort provided blood samples at day 0, day 14, and 10 months after the third-dose SARS-CoV-2 vaccine. Participants self-reported incident SARS-CoV-2 infection. Plasma anti-SARS-CoV-2 receptor-binding domain (RBD) and spike-subunit-1 and spike-subunit-2 antibodies were measured. A sub-study assessed SARS-CoV-2-specific plasma and memory B-cell and memory T-cell responses in peripheral blood mononuclear cells by enzyme-linked immunospot. Comparative analysis between participants who developed incident infection and uninfected participants utilised non-parametric t-tests, Kaplan-Meier survival analysis, and Cox proportional hazard ratios.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 132 participants, 47 (36%) reported incident SARS-CoV-2 infection at a median 16.5 (16.25-21) weeks after the third-dose vaccination. RBD titres and B-cell responses, but not T-cell responses, increased after the third-dose vaccine. Whereas no significant difference in day 14 antibody titres or T-cell responses was observed between participants with and without incident SARS-CoV-2 infection, RBD memory B-cell frequencies were significantly higher in those who did not develop infection [10.0% (4.5%-16.0%) versus 4.9% (1.6%-9.3%), p = 0.01]. RBD titres and memory B-cell frequencies remained significantly higher at 10 months than day 0 levels (p &lt; 0.01).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Robust antibody and B-cell responses persisted at 10 months following the third-dose vaccination. Higher memory B-cell frequencies, rather than antibody titres or T-cell responses, predicted protection from subsequent infection, identifying memory B cells as a correlate of protection.</AbstractText><CopyrightInformation>Copyright © 2024 Byrne, Gu, Garcia-Leon, Gaillard, Saini, Alalwan, Tomás-Cortázar, Kenny, Donohue, Reynolds, O’Gorman, Landay, Doran, Stemler, Koehler, Cox, Olesen, Lelievre, O’Broin, Savinelli, Feeney, O’Halloran, Cotter, Horgan, Kelly, Sadlier, de Barra, Cornely, Gautier, Mallon and All Ireland Infectious Diseases cohort study and VACCELERATE consortium.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Leon</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaillard</LastName><ForeName>Colette Marie</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saini</LastName><ForeName>Gurvin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alalwan</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomás-Cortázar</LastName><ForeName>Julen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Bearach</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Gorman</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landay</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doran</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stemler</LastName><ForeName>Jannik</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koehler</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Rebecca Jane</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olesen</LastName><ForeName>Ole F</ForeName><Initials>OF</Initials><AffiliationInfo><Affiliation>European Vaccine Initiative, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lelievre</LastName><ForeName>Jean-Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Vaccine Research Institute, Université Paris Est Créteil, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Broin</LastName><ForeName>Cathal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savinelli</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feeney</LastName><ForeName>Eoin R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Halloran</LastName><ForeName>Jane A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Aoife</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horgan</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadlier</LastName><ForeName>Corrina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Cork University Hospital, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Barra</LastName><ForeName>Eoghan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornely</LastName><ForeName>Oliver A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Partner Site Bonn-Cologne Department Cologne, German Centre for Infection Research (DZIF), Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautier</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>Patrick Wg</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="Y">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091245" MajorTopicYN="N">Memory B Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cells</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword></KeywordList><CoiStatement>JS has received research support by the German Ministry of Education and Research BMBF, Basilea Pharmaceuticals, Noscendo; has received speaker honoraria by AbbVie, Gilead, Hikma and Pfizer; has been a consultant to Gilead, Alvea Vax. and Micron Research PK reports grants or contracts from German Federal Ministry of Research and Education BMBF B-FAST Bundesweites Forschungsnetz Angewandte Surveillance und Testung and NAPKON Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network of the Network University Medicine NUM and the State of North Rhine-Westphalia; Consulting fees Ambu GmbH, Gilead Sciences, infill healthcare communication GmbH, Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., Datamed GmbH, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Jazz Pharmaceuticals Germany GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia GmbH, MSD Sharp &amp; Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC, streamedup! GmbH, University Hospital and LMU Munich and VITIS GmbH; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; A filed patent at the German Patent and Trade Mark Office DE 10 2021 113 007.7; Other non-financial interests from Elsevier, Wiley and Taylor &amp; Francis online outside the submitted work. SS has received financial support by Gilead Sciences, ViiV Healthcare, and MSD for attendance to international conferences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355249</ArticleId><ArticleId IdType="pmc">PMC11442242</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1445653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. . mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. (2021) 592:616–22. doi: 10.1038/s41586-021-03324-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03324-6</ArticleId><ArticleId IdType="pmc">PMC8503938</ArticleId><ArticleId IdType="pubmed">33567448</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D, et al. . Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discovery. (2022) 8:10. doi: 10.1038/s41421-022-00373-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-022-00373-7</ArticleId><ArticleId IdType="pmc">PMC8803973</ArticleId><ArticleId IdType="pubmed">35102140</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. . SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. (2021) 596:109–13. doi: 10.1038/s41586-021-03738-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03738-2</ArticleId><ArticleId IdType="pmc">PMC8935394</ArticleId><ArticleId IdType="pubmed">34182569</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty J, O'Morain N, Stack R, Tosetto M, Inzitiari R, O'Reilly S, et al. . Reduced serological response to COVID-19 booster vaccine is associated with reduced B cell memory in patients with inflammatory bowel disease; VARIATION [VAriability in response in IBD againsT SARS-COV-2 immunisatiON. J Crohns Colitis. (2023) 17:1445–56. doi: 10.1093/ecco-jcc/jjad065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjad065</ArticleId><ArticleId IdType="pubmed">37018462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Rouers A, Fong SW, Goh YS, Chan YH, Chang ZW, et al. . Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. EMBO Mol Med. (2022) 14:e15227. doi: 10.15252/emmm.202115227</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202115227</ArticleId><ArticleId IdType="pmc">PMC8899913</ArticleId><ArticleId IdType="pubmed">34994081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. . Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. (2021) 385:1474–84. doi: 10.1056/NEJMoa2109072</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109072</ArticleId><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. . Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. (2021) 384:533–40. doi: 10.1056/NEJMoa2034545</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034545</ArticleId><ArticleId IdType="pmc">PMC7781098</ArticleId><ArticleId IdType="pubmed">33369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. (2021) 27:2032–40. doi: 10.1038/s41591-021-01540-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. (2021) 27:1205–11. doi: 10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. . Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. (2021) 39:4423–8. doi: 10.1016/j.vaccine.2021.05.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.063</ArticleId><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis C, Logan N, Tyson G, Orton R, Harvey WT, Perkins JS, et al. . Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. (2021) 17:e1010022. doi: 10.1371/journal.ppat.1010022</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010022</ArticleId><ArticleId IdType="pmc">PMC8639073</ArticleId><ArticleId IdType="pubmed">34855916</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. . Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. (2021) 29:516–21.e3. doi: 10.1016/j.chom.2021.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.009</ArticleId><ArticleId IdType="pmc">PMC7980225</ArticleId><ArticleId IdType="pubmed">33798491</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M, et al. . Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One. (2022) 17:e0266852. doi: 10.1371/journal.pone.0266852</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266852</ArticleId><ArticleId IdType="pmc">PMC8993021</ArticleId><ArticleId IdType="pubmed">35395052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, O’Reilly S, Wrigley Kelly N, Negi R, Gaillard C, Alalwan D, et al. . Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time. Nat Commun. (2023) 14. doi: 10.1038/s41467-023-42717-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42717-1</ArticleId><ArticleId IdType="pmc">PMC10622572</ArticleId><ArticleId IdType="pubmed">37919289</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. . BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. (2021) 595:572–7. doi: 10.1038/s41586-021-03653-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03653-6</ArticleId><ArticleId IdType="pubmed">34044428</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinscheid M, Luxenburger H, Karl V, Graeser A, Giese S, Ciminski K, et al. . COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. Nat Commun. (2022) 13:4631. doi: 10.1038/s41467-022-32324-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32324-x</ArticleId><ArticleId IdType="pmc">PMC9358914</ArticleId><ArticleId IdType="pubmed">35941157</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter MM, Johnston TS, Lundgreen KA, Santos JJS, Qin JS, Goel RR, et al. . Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Nat Immunol. (2023) 24:1711–24. doi: 10.1038/s41590-023-01613-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01613-y</ArticleId><ArticleId IdType="pubmed">37735592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. . Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. (2022) 13:80. doi: 10.1038/s41467-021-27674-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27674-x</ArticleId><ArticleId IdType="pmc">PMC8748880</ArticleId><ArticleId IdType="pubmed">35013199</ArticleId></ArticleIdList></Reference><Reference><Citation>Available online at: https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/surveillance/summaryofcovid-19virusvariantsinIreland/. (Accessed May 10, 2024)</Citation></Reference><Reference><Citation>Kenny G, Negi R, O’Reilly S, Garcia-Leon A, Alalwan D, Gaillard CM, et al. . Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination. J Immunol Methods. (2022) 510:113345. doi: 10.1016/j.jim.2022.113345</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2022.113345</ArticleId><ArticleId IdType="pmc">PMC9425705</ArticleId><ArticleId IdType="pubmed">36055441</ArticleId></ArticleIdList></Reference><Reference><Citation>
Organisation WH . Living guidance for clinical management of COVID-19(2021). Available online at: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. (Accessed May 10, 2024)</Citation></Reference><Reference><Citation>Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, et al. . Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. (2021) 54:2133–42.e3. doi: 10.1016/j.immuni.2021.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.08.001</ArticleId><ArticleId IdType="pmc">PMC8361141</ArticleId><ArticleId IdType="pubmed">34453880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. (2010) 33:451–63. doi: 10.1016/j.immuni.2010.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC3760154</ArticleId><ArticleId IdType="pubmed">21029957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Galvez RI, et al. . Humoral and cellular immune memory to four COVID-19 vaccines. Cell. (2022) 185:2434–51.e17. doi: 10.1016/j.cell.2022.05.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.05.022</ArticleId><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklmeier S, Eisenhut K, Taskin D, Rubsamen H, Gerhards R, Schneider C, et al. . Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. iScience. (2022) 25:103659. doi: 10.1016/j.isci.2021.103659</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103659</ArticleId><ArticleId IdType="pmc">PMC8686444</ArticleId><ArticleId IdType="pubmed">34957380</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JS, Zhou JQ, Han J, Schmitz AJ, Rizk AA, Alsoussi WB, et al. . Human germinal centres engage memory and naive B cells after influenza vaccination. Nature. (2020) 586:127–32. doi: 10.1038/s41586-020-2711-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2711-0</ArticleId><ArticleId IdType="pmc">PMC7566073</ArticleId><ArticleId IdType="pubmed">32866963</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, et al. . Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. (2022) 185:1025–40.e14. doi: 10.1016/j.cell.2022.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.018</ArticleId><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward AC, Wang L, Goonetilleke N, Fragaszy EB, Bermingham A, Copas A, et al. . Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study. Am J Respir Crit Care Med. (2015) 191:1422–31. doi: 10.1164/rccm.201411-1988OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201411-1988OC</ArticleId><ArticleId IdType="pmc">PMC4476562</ArticleId><ArticleId IdType="pubmed">25844934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. . Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. (2013) 19:1305–12. doi: 10.1038/nm.3350</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3350</ArticleId><ArticleId IdType="pubmed">24056771</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Peng P, Cao X, Wu K, Chen J, Wang K, et al. . Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell Mol Immunol. (2022) 19:293–5. doi: 10.1038/s41423-021-00836-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00836-z</ArticleId><ArticleId IdType="pmc">PMC8749347</ArticleId><ArticleId IdType="pubmed">35017716</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. . Plasma neutralization of the SARS-CoV-2 omicron variant. N Engl J Med. (2022) 386:599–601. doi: 10.1056/NEJMc2119641</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119641</ArticleId><ArticleId IdType="pmc">PMC8757565</ArticleId><ArticleId IdType="pubmed">35030645</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. . mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. (2022) 185:457–66.e4. doi: 10.1016/j.cell.2021.12.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Van Beek M, Wang Z, Muecksch F, Canis M, Hatziioannou T, et al. . Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain. Cell Rep. (2023) 42:112256. doi: 10.1016/j.celrep.2023.112256</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112256</ArticleId><ArticleId IdType="pmc">PMC9986127</ArticleId><ArticleId IdType="pubmed">36952347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Zhou JQ, Horvath SC, Schmitz AJ, Sturtz AJ, Lei T, et al. . Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature. (2022) 604:141–5. doi: 10.1038/s41586-022-04527-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04527-1</ArticleId><ArticleId IdType="pmc">PMC9204750</ArticleId><ArticleId IdType="pubmed">35168246</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. . Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. (2022) 607:128–34. doi: 10.1038/s41586-022-04778-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04778-y</ArticleId><ArticleId IdType="pmc">PMC9259484</ArticleId><ArticleId IdType="pubmed">35447027</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>